| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
CD4+ T cells via HLA-DRB molecules. Tetanus toxin (830-843) is a bioactive peptide that acts as a CD4+ T cell epitope derived from tetanus toxin. It binds to various HLA-DRB molecules, potentially activating CD4+ T cell responses. As a fragment of the full toxin, it targets the cellular machinery involved in neurotransmitter release.
|
|---|---|
| ln Vitro |
Tetanus toxin (830-843) TFA is a CD4+ T cell epitope derived from tetanus toxin. This peptide binds to various HLA-DRB molecules and is therefore expected to activate CD4+ T cell responses in a large proportion of the population. It is used to study T cell activation and neurotoxin mechanism. The TFA salt is used to enhance solubility and stability.
|
| ln Vivo |
In vivo, tetanus toxin (830-843) may be used to study the immune response to tetanus toxin fragments. The full-length toxin causes spastic paralysis by blocking neurotransmitter release from inhibitory interneurons. This fragment, while derived from a neurotoxin, is not the full toxin and is used primarily for immunological studies.
|
| Enzyme Assay |
HLA-DR binding assay: Immobilized recombinant HLA-DR molecules on ELISA plates are incubated with increasing concentrations of Tetanus toxin (830-843) TFA (0-1000 nM) in binding buffer. After washing, bound peptide is detected with a labeled anti-peptide antibody or by biotin-streptavidin-HRP detection. The IC50 for HLA-DR binding is calculated by non-linear regression.
|
| Cell Assay |
T cell activation assay: Human peripheral blood mononuclear cells (PBMCs) are isolated and seeded in 96-well plates. Tetanus toxin (830-843) TFA (0.1-100 ug/mL) is added to the cultures. After 5-7 days, T cell proliferation is measured by 3H-thymidine incorporation or CFSE dilution. Activation markers (CD25, CD69) on CD4+ T cells are analyzed by flow cytometry, and cytokines (IFN-gamma, IL-2, IL-4) are measured by ELISA.
|
| Animal Protocol |
Tetanus toxin challenge model (for full toxin): For the full toxin, animal models of spastic paralysis are used. However, this peptide fragment is typically not administered alone. It may be used to study immune responses in mice immunized with tetanus toxoid. Tetanus toxin (830-843) TFA is used to restimulate T cells ex vivo from immunized animals to measure recall responses.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Tetanus toxin (830-843) TFA are not available. As a peptide (MW 1725.86, TFA salt), it is soluble in DMSO and water. The TFA salt is used to enhance peptide stability and solubility. For storage, the lyophilized powder should be kept at -20degC, sealed, and protected from light and moisture.
|
| Toxicity/Toxicokinetics |
Toxicity data for Tetanus toxin (830-843) TFA are not reported. As a peptide fragment, it does not possess the full neurotoxic activity of the holotoxin. The full tetanus toxin causes severe spastic paralysis. This fragment is considered much less toxic and is used for research purposes only. Standard safety precautions should be followed.
|
| References |
[1]. Diethelm-Okita BM, et al. Epitope repertoire of human CD4+ T cells on tetanus toxin: identification of immunodominant sequence segments. J Infect Dis. 1997 Feb;175(2):382-91.
|
| Additional Infomation |
Tetanus toxin (830-843) TFA is a research-grade peptide fragment used for immunological and neurobiological studies. It is not a drug candidate and has not been approved for human therapeutic use. The peptide sequence corresponds to a well-known T cell epitope from tetanus toxoid, frequently used in vaccine research. For research use only.
|
| Molecular Formula |
C76H119F3N18O24
|
|---|---|
| Molecular Weight |
1725.86
|
| Related CAS # |
Tetanus toxin (830-843);119260-99-0
|
| Appearance |
Typically exists as solid at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~18.18 mg/mL (~10.53 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.5794 mL | 2.8971 mL | 5.7942 mL | |
| 5 mM | 0.1159 mL | 0.5794 mL | 1.1588 mL | |
| 10 mM | 0.0579 mL | 0.2897 mL | 0.5794 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
